News & Updates

Ipilimumab therapy may improve survival in uveal, mucosal melanoma

06 Mar 2020

Treatment with ipilimumab appears to increase survival in patients with uveal and mucosal melanoma, according to a multicentre, retrospective study.

Ipilimumab therapy may improve survival in uveal, mucosal melanoma

06 Mar 2020

Electronic nose sniffs out Barrett’s oesophagus

06 Mar 2020 by

A high atherogenic index of plasma (AIP) is a strong risk factor for developing subclinical renal damage (SRD) and is associated with estimated glomerular filtration rate (eGFR) and urinary albumin-to-creatine ratio (uACR), a recent study has shown.A novel electronic nose device can reliably detect Barrett’s oesophagus (BO) and may present an efficient, minimally invasive option for early detection of oesophageal adenocarcinoma (OAC), according to a recent study.

Electronic nose sniffs out Barrett’s oesophagus

06 Mar 2020

Molecularly guided therapy extends OS by 1 year in pancreatic cancer in real-world settings

06 Mar 2020 by

Patients with pancreatic cancer with actionable mutations may have their overall survival (OS) extended by 1 year with molecularly matched therapies compared with unmatched therapies, a retrospective analysis of real-world data has shown.

Molecularly guided therapy extends OS by 1 year in pancreatic cancer in real-world settings

06 Mar 2020

Obinutuzumab plus fludarabine, cyclophosphamide feasible for fit CLL patients

06 Mar 2020 by

A regimen consisting of obinutuzumab plus fludarabine and cyclophosphamide achieves favourable outcomes with manageable toxicity in the treatment of chronic lymphocytic leukaemia (CLL) in physically fit adults, poised as an attractive first-line option in patients who are eligible for potent chemoimmunotherapy, according to data from the phase IIIb GREEN trial.

Obinutuzumab plus fludarabine, cyclophosphamide feasible for fit CLL patients

06 Mar 2020

Perception of cancer risk poor among women seeking genetic cancer risk assessment

05 Mar 2020

Despite showing great concern that they may develop hereditary breast and ovarian cancer, women undergoing genetic cancer risk assessment believe that their risk of malignancy is equal to that of the general population, a new study has found.

Perception of cancer risk poor among women seeking genetic cancer risk assessment

05 Mar 2020

Nivolumab continues positive OS, ORR track record in advanced RCC

05 Mar 2020 by

Patients with previously treated advanced or metastatic clear cell renal cell carcinoma (RCC) appear to derive greater overall survival (OS) benefit with nivolumab compared with everolimus, according to final results of the phase III CheckMate 025* trial presented at ASCO GU 2020.

Nivolumab continues positive OS, ORR track record in advanced RCC

05 Mar 2020

Realizing the potential of stereotactic ablative radiotherapy for primary renal cell carcinoma

05 Mar 2020 by

Stereotactic ablative radiotherapy (SABR) has shown promising results in primary renal cell carcinoma (RCC) in recent trials and has become a treatment option for patients with inoperable primary RCC or tumours in solitary kidney, said Dr Shankar Siva of the Peter MacCallum Cancer Centre of Melbourne, Australia, at the Uro-Oncology Asia 2020 conference.

Realizing the potential of stereotactic ablative radiotherapy for primary renal cell carcinoma

05 Mar 2020

Everolimus, letrozole, metformin: Triple threat against recurrent endometrial cancer

04 Mar 2020

The combination of metformin, everolimus and letrozole has demonstrated clinical activity in patients with recurrent endometrioid endometrial cancer (EEC), inducing better response in those with progesterone receptor (PgR)-positive tumours, according to the results of a phase II study.

Everolimus, letrozole, metformin: Triple threat against recurrent endometrial cancer

04 Mar 2020

ASCO’s 2020 Advance of the Year: Systemic therapies refine cancer surgical treatment

04 Mar 2020 by

The American Society of Clinical Oncology (ASCO) has named the refinement of surgical treatment of cancer as 2020 Advance of the Year.

ASCO’s 2020 Advance of the Year: Systemic therapies refine cancer surgical treatment

04 Mar 2020

Mammography screening: When to stop?

03 Mar 2020 by

Continuing mammography screening annually might not benefit healthy women aged 75 years and above, suggests a large-scale, population-based study in the US.

Mammography screening: When to stop?

03 Mar 2020

News & Updates

Filter by Specialty:

Specialty:

Ipilimumab therapy may improve survival in uveal, mucosal melanoma

Ipilimumab therapy may improve survival in uveal, mucosal melanoma

Electronic nose sniffs out Barrett’s oesophagus

Electronic nose sniffs out Barrett’s oesophagus

Molecularly guided therapy extends OS by 1 year in pancreatic cancer in real-world settings

Molecularly guided therapy extends OS by 1 year in pancreatic cancer in real-world settings

Obinutuzumab plus fludarabine, cyclophosphamide feasible for fit CLL patients

Obinutuzumab plus fludarabine, cyclophosphamide feasible for fit CLL patients

Perception of cancer risk poor among women seeking genetic cancer risk assessment

Perception of cancer risk poor among women seeking genetic cancer risk assessment

Nivolumab continues positive OS, ORR track record in advanced RCC

Nivolumab continues positive OS, ORR track record in advanced RCC

Realizing the potential of stereotactic ablative radiotherapy for primary renal cell carcinoma

Realizing the potential of stereotactic ablative radiotherapy for primary renal cell carcinoma

Everolimus, letrozole, metformin: Triple threat against recurrent endometrial cancer

Everolimus, letrozole, metformin: Triple threat against recurrent endometrial cancer

ASCO’s 2020 Advance of the Year: Systemic therapies refine cancer surgical treatment

ASCO’s 2020 Advance of the Year: Systemic therapies refine cancer surgical treatment

Mammography screening: When to stop?

Mammography screening: When to stop?